GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Cash, Cash Equivalents, Marketable Securities

BriaCell Therapeutics (FRA:8BT0) Cash, Cash Equivalents, Marketable Securities : €4.84 Mil (As of Jan. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Cash, Cash Equivalents, Marketable Securities?

BriaCell Therapeutics's quarterly cash, cash equivalents, marketable securities increased from Jul. 2024 (€0.80 Mil) to Oct. 2024 (€5.32 Mil) but then stayed the same from Oct. 2024 (€5.32 Mil) to Jan. 2025 (€4.84 Mil).

BriaCell Therapeutics's annual cash, cash equivalents, marketable securities declined from Jul. 2022 (€40.34 Mil) to Jul. 2023 (€19.21 Mil) and declined from Jul. 2023 (€19.21 Mil) to Jul. 2024 (€0.80 Mil).


BriaCell Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for BriaCell Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 48.45 40.34 19.21 0.80

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.73 0.87 0.80 5.32 4.84

BriaCell Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


BriaCell Therapeutics  (FRA:8BT0) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


BriaCell Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines